{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Interpace Biosciences Announces CFO Leadership Transition - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"pw1joVHSDX\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/interpace-biosciences-announces-cfo-leadership-transition\/\">Interpace Biosciences Announces CFO Leadership Transition<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/interpace-biosciences-announces-cfo-leadership-transition\/embed\/#?secret=pw1joVHSDX\" width=\"600\" height=\"338\" title=\"&#8220;Interpace Biosciences Announces CFO Leadership Transition&#8221; &#8212; Market Newsdesk\" data-secret=\"pw1joVHSDX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) &#8212; Interpace Biosciences, Inc. (NASDAQ: IDXG) (\u201cInterpace\u201d) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace\u2019s Chief Financial Officer (\u201cCFO\u201d). Mr. Freeburg succeeds Fred Knechtel effective February 1, 2021. Mr. Freeburg has been with Interpace since 2017 and brings over 20 years of financial and executive experience to his new role. As Chief Accounting Officer, he has led the company&#8217;s Financial Reporting, Treasury, Financial Planning and Analysis (FP&amp;A), Risk Management &amp; Insurance and Corporate Development functions. Prior to Interpace, Tom served in senior finance roles at several other companies, where his responsibilities included Financial Reporting, Capital Markets, Treasury and FP&amp;A. &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0Nzc1OCMzOTYyMDY2IzUwMDA1MDI0MQ=="}